1. Home
  2. EARN vs ENLV Comparison

EARN vs ENLV Comparison

Compare EARN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.41

Market Cap

169.8M

Sector

Real Estate

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

N/A

Current Price

$1.47

Market Cap

149.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EARN
ENLV
Founded
2012
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.8M
149.0M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
EARN
ENLV
Price
$4.41
$1.47
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$5.38
$20.00
AVG Volume (30 Days)
409.0K
310.9K
Earning Date
06-16-2026
05-29-2026
Dividend Yield
20.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.69
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$0.43
52 Week High
$5.89
$7.64

Technical Indicators

Market Signals
Indicator
EARN
ENLV
Relative Strength Index (RSI) 52.49 36.93
Support Level $4.29 $0.70
Resistance Level $4.48 $1.81
Average True Range (ATR) 0.07 0.23
MACD 0.01 -0.08
Stochastic Oscillator 78.26 10.34

Price Performance

Historical Comparison
EARN
ENLV

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: